| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.1M | +415.7% |
| SG&A Expense | $3.4M | +78.2% |
| Operating Income | -$5.6M | -137.8% |
| Net Income | -$5.4M | -109.3% |
| EPS (Basic) | -$0.30 | -30.4% |
| EPS (Diluted) | -$0.30 | -30.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.5M | +253.1% |
| Current Assets | $5.4M | +29.2% |
| Total Assets | $6.5M | +13.4% |
| Current Liabilities | $199K | -79.9% |
| Stockholders' Equity | $6.3M | +32.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$3.4M | +13.0% |
| Financing Cash Flow | $6.7M | +29.7% |